Tucatinib

Drug Profile

Tucatinib

Alternative Names: ARRY-380; Irbinitinib; ONT-380

Latest Information Update: 14 Dec 2016

Price : $50

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; Cascadian Therapeutics; Dana-Farber Cancer Institute
  • Class 2 ring heterocyclic compounds; Antineoplastics; Diamines; Furans; Pyridines; Quinazolinones; Small molecules; Triazoles
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Breast cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer
  • Phase I Solid tumours

Most Recent Events

  • 07 Dec 2016 Interim updated adverse events and efficacy data from the phase Ib HER2CLIMB trial in Breast cancer presented at the San Antonio Breast Cancer Symposium (SABCS-2016)
  • 10 Oct 2016 Efficacy data from a phase Ib trial in Breast cancer demonstrating responses of skin lesions presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 07 Oct 2016 Efficacy data from a phase Ib trial in Breast cancer presented at the 41st European Society for Medical Oncology Congress-2016 (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top